COMMUNIQUÉS West-GlobeNewswire

Advantis Corp. Partners with NFL Great, Kyle Turley, Expands Product Lineup Three-Fold

22/10/2018 - 15:00

NEWPORT BEACH, CA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ADVANTIS CORPORATION (OTC PINK: ADVT) announced that is has partnered with former NFL offensive lineman, Kyle Turley, to help market and distribute [...]

Clients save Millions in Drug Spend through the use of Innovative Pharmacy Analytics for Hospitals and Health Systems

22/10/2018 - 15:00

Comprehensive Pharmacy Services RxClinical Analytics 2.0 is a Gamechanger for Managing Drug Hyperinflation and Clinical Performance MEMPHIS, Tenn., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Comprehensive Pharmacy Services (CPS [...]

Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC

22/10/2018 - 14:45

– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC patient dosed outside [...]

Novo Nordisk A/S - Share repurchase programme

22/10/2018 - 14:42

Bagsværd, Denmark, 22 October 2018 - On 10 August 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]

Cybrexa Therapeutics Expands Scientific Advisory Board Ahead of IND Filing

22/10/2018 - 14:38

Dr. Geoffrey Shapiro and Dr. Timothy Yap bring extensive expertise in targeting cell-cycle and DNA repair mechanisms in oncology drug development NEW HAVEN, Conn., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics [...]

Transactions under Novozymes’ stock buyback program

22/10/2018 - 14:36

Please read the full announcement in the attached PDF Attachment 2018_59_Stock_Buybackprogram_EN

Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress

22/10/2018 - 14:30

Predictive biomarker can potentially identify patients most likely to benefit from CPI-444 and other therapies targeting the adenosine pathway BURLINGAME, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals [...]

Hemispherx Outlines Ampligen Combination Therapy Clinical Study Strategy for the Treatment of Multiple Cancers in Letter to Stockholders

22/10/2018 - 14:30

ORLANDO, Fla., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to Stockholders providing a [...]

Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences

22/10/2018 - 14:30

CALGARY, Alberta, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at premier conferences including the American Society of Nephrology ( [...]

MyoKardia to Host R&D Day on October 30, 2018

22/10/2018 - 14:30

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today [...]

VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018

22/10/2018 - 14:30

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- VistaGen Therapeutics Inc ( NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) [...]

Arbutus Names New Members to its Board of Directors

22/10/2018 - 14:30

WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James Meyers and Myrtle [...]

Nuvectra® to Report Third Quarter 2018 Financial Results on October 29, 2018

22/10/2018 - 14:01

PLANO, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended [...]

Sharp Rees-Stealy Medical Group leverages Allscripts EHR to achieve HIMSS Analytics O-EMRAM Stage 7

22/10/2018 - 14:01

San Diego's leading health care provider recognized for optimal use of Allscripts TouchWorks® EHR solution CHICAGO, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Allscripts (NASDAQ: MDRX) client Sharp HealthCare’s affiliated [...]

Dentsply Sirona to Host Third Quarter 2018 Conference Call on November 8th

22/10/2018 - 14:00

YORK, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (NASDAQ:XRAY), The Dental Solutions Company™, today announced that the Company will host an investor conference call and live webcast on Thursday, [...]

Relypsa Announces Presentation of New Clinical and Real-World Analyses of Veltassa® at AMCP Nexus 2018

22/10/2018 - 14:00

REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, will present new data on Veltassa® (patiromer) at the Academy of Managed Care Pharmacy’s AMCP Nexus 2018 conference in [...]

Results from Celtaxsys’ Acebilustat Phase 2 Trial in Cystic Fibrosis Patients Showing Clinically Meaningful Improvement in Pulmonary Exacerbations Presented at the North American Cystic Fibrosis Conference

22/10/2018 - 14:00

ATLANTA, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, today announced that results [...]

Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346

22/10/2018 - 14:00

Data Presented in Poster Session at 2018 ACR/ARHP Annual Meeting NEWTON, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to [...]

Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150

22/10/2018 - 14:00

Study Results Presented at a Major European Cancer Conference (ESMO) PLYMOUTH MEETING, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that new data from the company’s [...]